Elliott J. Hagedorn

Elliott J. Hagedorn

Auto-generated profile, based on publicly available information

Elliott J. Hagedorn

Department of Medicine, Section of Hematology and Medical Oncology, Boston University Chobanian & Avedisian School of Medicine and Boston Medical Center, Boston, MA, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 September 2022 in Science
Verified
Journal Article
Open access
SWSamuel J. Wattrus
Samuel J. Wattrus
MSMackenzie L. Smith
Mackenzie L. Smith
CRCecilia Pessoa Rodrigues
Cecilia Pessoa Rodrigues
EHElliott J. Hagedorn
Elliott J. Hagedorn
JKJi Wook Kim
Ji Wook Kim
LZLeonard I. Zon
Leonard I. Zon
Tissue-specific stem cells persist for a lifetime and can differentiate to maintain homeostasis or transform to initiate cancer. Despite their importance, there are no described quality assurance mechanisms for newly formed stem cells. We observed intimate and specific interactions between macrophages and nascent blood stem cells in zebrafish embryos. Macrophage interactions frequently led to either removal of cytoplasmic material and stem cell division or complete engulfment and stem cell death. Stressed stem cells were marked by surface Calreticulin, which stimulated macrophage interactions. Using cellular barcoding, we found that Calreticulin knock-down or embryonic macrophage depletion reduced the number of stem cell clones that established adult hematopoiesis. Our work supports a model in which embryonic macrophages determine hematopoietic clonality by monitoring stem cell quality.

14 May 2021 in Science
Verified
Journal Article
Closed access
MRMarlies P. Rossmann
Marlies P. Rossmann
KHKaren Hoi
Karen Hoi
VCVictoria Chan
Victoria Chan
BABrian J. Abraham
Brian J. Abraham
SYSong Yang
Song Yang
LZLeonard I. Zon
Leonard I. Zon
Metabolic pathway regulates cell fate: Lineage-specific regulators direct cell fate decisions, but the precise mechanisms are not well known. Using an in vivo chemical suppressor screen of a bloodless zebrafish mutant, Rossmann et al. show that the lineage-specific chromatin factor tif1γ directly regulates mitochondrial genes to drive red blood cell differentiation. Loss of tif1γ reduces coenzyme Q synthesis and function, impeding mitochondrial respiration and leading to epigenetic alterations and repression of erythropoiesis. The loss of blood in the mutant fish can be rescued by the addition of coenzyme Q. This work establishes a mechanism by which a chromatin factor tunes a metabolic pathway in a tissue-specific manner. Science , this issue p. 716

4 November 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
EHElliott J. Hagedorn
Elliott J. Hagedorn
JPJulie R. Perlin
Julie R. Perlin
RFRebecca J. Freeman
Rebecca J. Freeman
SWSamuel J. Wattrus
Samuel J. Wattrus
THTianxiao Han
Tianxiao Han
LZLeonard I. Zon
Leonard I. Zon
The hematopoietic niche is a supportive microenvironment comprised of distinct cell types, including specialized vascular endothelial cells that directly interact with hematopoietic stem and progenitor cells (HSPCs). The molecular factors that specify niche endothelial cells and orchestrate HSPC homeostasis remain largely unknown. Using multi-dimensional gene expression and chromatin accessibility analyses, we define a conserved gene expression signature and cis -regulatory landscape unique to sinusoidal endothelial cells in the HSPC niche. Using enhancer mutagenesis and transcription factor overexpression, we elucidate a transcriptional code involving members of the Ets, Sox and Nuclear Hormone Receptor families that is sufficient to induce ectopic niche endothelial cells that associate with mesenchymal stromal cells and support the recruitment, maintenance and division of HSPCs in vivo . These studies set forth an approach for generating synthetic HSPC niches, in vitro or in vivo , and for effective therapies to modulate the endogenous niche.

8 July 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
GBGwendolyn M. Beacham
Gwendolyn M. Beacham
ZIZewde Ingram
Zewde Ingram
REReema A. Elrefaie
Reema A. Elrefaie
KEKhaliun Enkhbayar
Khaliun Enkhbayar
ZZZachary R. Zener
Zachary R. Zener
EHElliott J. Hagedorn
Elliott J. Hagedorn
Hematopoietic stem and progenitor cell (HSPC) niches support lifelong production of blood and immune cells. Recently, we identified a gene signature unique to HSPC niche endothelial cells that is highly conserved across species and developmental time and includes the scavenger receptors stab1/2 and mrc1a . Whether these receptors support HSPC development remains unclear. To investigate this, we used chemical inhibition and CRISPR mutagenesis in zebrafish and found that loss of stab2 , and to a lesser degree stab1 , reduced the number of embryonic runx1 (+) HSPCs. Subsequent analyses of an additional HSPC marker ( cd41 ) revealed an imbalance in the HSPC pool in stab2 mutants, with reductions in runx1 (+) cd41 (+) and runx1 (+) cd41 (-) sub-populations containing stem cells and erythroid progenitors, respectively, the latter of which was most decreased. Our findings suggest stabilin scavenger receptors support HSPC development in the fetal niche, which could inform clinical strategies for culturing and expanding HSPCs.

23 June 2026 in Blood Advances
Verified
Journal Article
Open access
HBHajar Benmhammed
Hajar Benmhammed
YSYanan Sun
Yanan Sun
SASalam AlAbdullatif
Salam AlAbdullatif
ACAndrew Chen
Andrew Chen
SKSerena Khan
Serena Khan
SCShuaiying Cui
Shuaiying Cui
Sickle cell disease (SCD), caused by a point mutation in the β-globin gene (HBB), results in the production of sickle hemoglobin (HbS). Deoxy-HbS polymerizes, deforming red blood cells (RBCs) and leading to a cascade of clinical complications, including vaso-occlusion, hemolysis, inflammation, and progressive organ damage. An effective strategy to mitigate disease severity is the reactivation of fetal hemoglobin (HbF), which interferes with HbS polymerization. We explored the therapeutic potential of ZLN005, a small-molecule activator of the transcriptional coactivator PGC-1α (peroxisome proliferator–activated receptor gamma coactivator 1-α), by evaluating its impact on HbF induction in CD34+ hematopoietic progenitor cells derived from patients with SCD, in β-YAC transgenic mice carrying a normal human HBB cluster, and in SCD mice. ZLN005 increased γ-globin expression and HbF+ cells without impairing erythroid differentiation of CD34+ cells. Oral administration of ZLN005 to SCD mice increased HbF+ cells, reduced sickled RBCs, increased hemoglobin levels, lowered reticulocyte counts, and decreased spleen and liver pathology related to SCD. ZLN005 or related compounds could represent a promising new class of orally available HbF-inducing therapeutics.